FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3157453497> ?p ?o ?g. }

• W3157453497 endingPage "778" @default.
• W3157453497 startingPage "765" @default.
• W3157453497 abstract "BackgroundThe efficacy and safety profiles of vaccines against SARS-CoV-2 in patients with cancer is unknown. We aimed to assess the safety and immunogenicity of the BNT162b2 (Pfizer–BioNTech) vaccine in patients with cancer.MethodsFor this prospective observational study, we recruited patients with cancer and healthy controls (mostly health-care workers) from three London hospitals between Dec 8, 2020, and Feb 18, 2021. Participants who were vaccinated between Dec 8 and Dec 29, 2020, received two 30 μg doses of BNT162b2 administered intramuscularly 21 days apart; patients vaccinated after this date received only one 30 μg dose with a planned follow-up boost at 12 weeks. Blood samples were taken before vaccination and at 3 weeks and 5 weeks after the first vaccination. Where possible, serial nasopharyngeal real-time RT-PCR (rRT-PCR) swab tests were done every 10 days or in cases of symptomatic COVID-19. The coprimary endpoints were seroconversion to SARS-CoV-2 spike (S) protein in patients with cancer following the first vaccination with the BNT162b2 vaccine and the effect of vaccine boosting after 21 days on seroconversion. All participants with available data were included in the safety and immunogenicity analyses. Ongoing follow-up is underway for further blood sampling after the delayed (12-week) vaccine boost. This study is registered with the NHS Health Research Authority and Health and Care Research Wales (REC ID 20/HRA/2031).Findings151 patients with cancer (95 patients with solid cancer and 56 patients with haematological cancer) and 54 healthy controls were enrolled. For this interim data analysis of the safety and immunogenicity of vaccinated patients with cancer, samples and data obtained up to March 19, 2021, were analysed. After exclusion of 17 patients who had been exposed to SARS-CoV-2 (detected by either antibody seroconversion or a positive rRT-PCR COVID-19 swab test) from the immunogenicity analysis, the proportion of positive anti-S IgG titres at approximately 21 days following a single vaccine inoculum across the three cohorts were 32 (94%; 95% CI 81–98) of 34 healthy controls; 21 (38%; 26–51) of 56 patients with solid cancer, and eight (18%; 10–32) of 44 patients with haematological cancer. 16 healthy controls, 25 patients with solid cancer, and six patients with haematological cancer received a second dose on day 21. Of the patients with available blood samples 2 weeks following a 21-day vaccine boost, and excluding 17 participants with evidence of previous natural SARS-CoV-2 exposure, 18 (95%; 95% CI 75–99) of 19 patients with solid cancer, 12 (100%; 76–100) of 12 healthy controls, and three (60%; 23–88) of five patients with haematological cancers were seropositive, compared with ten (30%; 17–47) of 33, 18 (86%; 65–95) of 21, and four (11%; 4–25) of 36, respectively, who did not receive a boost. The vaccine was well tolerated; no toxicities were reported in 75 (54%) of 140 patients with cancer following the first dose of BNT162b2, and in 22 (71%) of 31 patients with cancer following the second dose. Similarly, no toxicities were reported in 15 (38%) of 40 healthy controls after the first dose and in five (31%) of 16 after the second dose. Injection-site pain within 7 days following the first dose was the most commonly reported local reaction (23 [35%] of 65 patients with cancer; 12 [48%] of 25 healthy controls). No vaccine-related deaths were reported.InterpretationIn patients with cancer, one dose of the BNT162b2 vaccine yields poor efficacy. Immunogenicity increased significantly in patients with solid cancer within 2 weeks of a vaccine boost at day 21 after the first dose. These data support prioritisation of patients with cancer for an early (day 21) second dose of the BNT162b2 vaccine.FundingKing's College London, Cancer Research UK, Wellcome Trust, Rosetrees Trust, and Francis Crick Institute." @default.
• W3157453497 created "2021-05-10" @default.
• W3157453497 creator A5000168334 @default.
• W3157453497 creator A5000829593 @default.
• W3157453497 creator A5003141763 @default.
• W3157453497 creator A5003985815 @default.
• W3157453497 creator A5013066121 @default.
• W3157453497 creator A5013611309 @default.
• W3157453497 creator A5014364684 @default.
• W3157453497 creator A5015902231 @default.
• W3157453497 creator A5018812698 @default.
• W3157453497 creator A5019091151 @default.
• W3157453497 creator A5022124081 @default.
• W3157453497 creator A5025872990 @default.
• W3157453497 creator A5034026446 @default.
• W3157453497 creator A5034738625 @default.
• W3157453497 creator A5034748028 @default.
• W3157453497 creator A5035313756 @default.
• W3157453497 creator A5035405270 @default.
• W3157453497 creator A5035423417 @default.
• W3157453497 creator A5043870872 @default.
• W3157453497 creator A5045820092 @default.
• W3157453497 creator A5048086477 @default.
• W3157453497 creator A5048120106 @default.
• W3157453497 creator A5049714548 @default.
• W3157453497 creator A5054111078 @default.
• W3157453497 creator A5056715948 @default.
• W3157453497 creator A5057065551 @default.
• W3157453497 creator A5060584070 @default.
• W3157453497 creator A5061129114 @default.
• W3157453497 creator A5066883810 @default.
• W3157453497 creator A5069176195 @default.
• W3157453497 creator A5075689685 @default.
• W3157453497 creator A5075885901 @default.
• W3157453497 creator A5075959397 @default.
• W3157453497 creator A5078531274 @default.
• W3157453497 creator A5078967449 @default.
• W3157453497 creator A5082171636 @default.
• W3157453497 creator A5084351864 @default.
• W3157453497 creator A5084722080 @default.
• W3157453497 creator A5087403121 @default.
• W3157453497 creator A5089767652 @default.
• W3157453497 creator A5090201792 @default.
• W3157453497 creator A5090990111 @default.
• W3157453497 creator A5091115060 @default.
• W3157453497 creator A5091639782 @default.
• W3157453497 date "2021-06-01" @default.
• W3157453497 modified "2023-10-18" @default.
• W3157453497 title "Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study" @default.
• W3157453497 cites W1980312663 @default.
• W3157453497 cites W1999211903 @default.
• W3157453497 cites W2020073562 @default.
• W3157453497 cites W2914650668 @default.
• W3157453497 cites W3034366265 @default.
• W3157453497 cites W3045971896 @default.
• W3157453497 cites W3048160337 @default.
• W3157453497 cites W3048434629 @default.
• W3157453497 cites W3049325061 @default.
• W3157453497 cites W3085486156 @default.
• W3157453497 cites W3088689466 @default.
• W3157453497 cites W3090844627 @default.
• W3157453497 cites W3093667122 @default.
• W3157453497 cites W3094870207 @default.
• W3157453497 cites W3097738396 @default.
• W3157453497 cites W3102798166 @default.
• W3157453497 cites W3107586775 @default.
• W3157453497 cites W3111255098 @default.
• W3157453497 cites W3111852762 @default.
• W3157453497 cites W3120915765 @default.
• W3157453497 cites W3128154910 @default.
• W3157453497 cites W3129580280 @default.
• W3157453497 cites W3134208712 @default.
• W3157453497 cites W3135210768 @default.
• W3157453497 doi "https://doi.org/10.1016/s1470-2045(21)00213-8" @default.
• W3157453497 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8078907" @default.
• W3157453497 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33930323" @default.
• W3157453497 hasPublicationYear "2021" @default.
• W3157453497 type Work @default.
• W3157453497 sameAs 3157453497 @default.
• W3157453497 citedByCount "458" @default.
• W3157453497 countsByYear W31574534972021 @default.
• W3157453497 countsByYear W31574534972022 @default.
• W3157453497 countsByYear W31574534972023 @default.
• W3157453497 crossrefType "journal-article" @default.
• W3157453497 hasAuthorship W3157453497A5000168334 @default.
• W3157453497 hasAuthorship W3157453497A5000829593 @default.
• W3157453497 hasAuthorship W3157453497A5003141763 @default.
• W3157453497 hasAuthorship W3157453497A5003985815 @default.
• W3157453497 hasAuthorship W3157453497A5013066121 @default.
• W3157453497 hasAuthorship W3157453497A5013611309 @default.
• W3157453497 hasAuthorship W3157453497A5014364684 @default.
• W3157453497 hasAuthorship W3157453497A5015902231 @default.
• W3157453497 hasAuthorship W3157453497A5018812698 @default.
• W3157453497 hasAuthorship W3157453497A5019091151 @default.
• W3157453497 hasAuthorship W3157453497A5022124081 @default.
• W3157453497 hasAuthorship W3157453497A5025872990 @default.
• W3157453497 hasAuthorship W3157453497A5034026446 @default.
• W3157453497 hasAuthorship W3157453497A5034738625 @default.

• next